{
  "model": "granite3.3:2b",
  "status": "success",
  "data": {
    "report_id": {
      "date_collected": "",
      "date_received": "",
      "date_verified": "2020-12-09",
      "report_type": "Pathology",
      "testing_context": "Research",
      "ordering_clinic": "Toronto Cancer Hospital Division of Tumor Sequencing and Diagnostics, info@och.on.ca",
      "testing_laboratory": "North York General Hospital (Toronto)",
      "sequencing_scope": "Gene panel",
      "tested_genes": {
        "ATM": {
          "gene_symbol": "ATM",
          "refseq_mrna": "NM_000051.4"
        },
        "ACKR3": {
          "gene_symbol": "ACKR3",
          "refseq_mrna": "NM_020311.3"
        },
        "KDMGA": {
          "gene_symbol": "KDMGA",
          "refseq_mrna": "NM_001291415.2"
        }
      },
      "additional_genes": [
        "LRP2",
        "CCND3",
        "RHOH",
        "FANCD2",
        "ING4",
        "ACKR3",
        "GNAS",
        "MPO",
        "HMGA1",
        "KDMGA",
        "ZHX2",
        "CHDA",
        "PSIPI",
        "FOXA2",
        "PRRCZA",
        "TPM3",
        "BCLZA",
        "ATM"
      ]
    },
    "variants": [
      {
        "gene": "ATM",
        "variant": "c.1215G>A",
        "effect_class": "Pathogenic/Likely Pathogenic",
        "description": "Missense, R to H"
      },
      {
        "gene": "ACKR3",
        "variant": "c.904G>C",
        "effect_class": "Variant of Uncertain Significance (VUS)",
        "description": "Nonsense, R to X"
      },
      {
        "gene": "KDMGA",
        "variant": "c.3627A>T",
        "effect_class": "Variant of Uncertain Significance (VUS)",
        "description": "Missense, Ile1209="
      }
    ],
    "test_details": {
      "methodology": "RNA fractions sequenced with Gene panel and analyzed using Karyotyping",
      "variants_called": "Using GATK and VarSeq, annotated with population databases, predictive algorithms, and ClinVar"
    },
    "recommendations": [
      "Precision oncology approach advised. Targeted therapies, including hormone-correcting agents, may be considered; PI3K inhibitors could be explored for PIK3CA-mutated cases",
      "Germline testing is not indicated, as all mutations are consistent with somatic events",
      "Multidisciplinary tumor board review recommended to integrate findings into care"
    ],
    "limitations": [
      "Limited sensitivity in pseudogene regions (e.g., PMS2, CHEK2)",
      "Inability to detect certain structural variants (e.g., MSH2 inversions), deep intronic changes, or low-level mosaicism",
      "PMS2 exons 11-15 are not analyzed"
    ]
  },
  "timestamp": "2025-06-05",
  "source_file": "report_fakeHospital2__ed5ad1e3-7f4f-4e33-b2c6-2ea55d40f3e5.txt"
}